Ubiquitin receptors play redundant roles in the proteasomal degradation of the p53 repressor MDM2

被引:0
|
作者
Sparks, Alison [1 ]
Kelly, Christopher J. [1 ,2 ]
Saville, Mark K. [1 ,3 ]
机构
[1] Univ Dundee, Sch Med, Dundee, Scotland
[2] Univ Glasgow, Inst Infect Immun & Inflammat, Glasgow, Lanark, Scotland
[3] Silver River Editing, Dundee, Scotland
基金
欧洲研究理事会; 英国惠康基金;
关键词
ADRM1; PSMD16; hRpn13; MDM2; p53; TP53; proteasomal ubiquitin receptor; redundancy; S5A; PSMD4; hRpn10; MULTIUBIQUITIN-CHAIN-BINDING; 26 S PROTEASOME; POLYUBIQUITIN CHAINS; PROTEIN-DEGRADATION; CANCER DEPENDENCIES; LARGE-SCALE; VWA DOMAIN; RPN10; SUBUNIT; PROMOTES;
D O I
10.1002/1873-3468.14436
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Much remains to be determined about the participation of ubiquitin receptors in proteasomal degradation and their potential as therapeutic targets. Suppression of the ubiquitin receptor S5A/PSMD4/hRpn10 alone stabilises p53/TP53 but not the key p53 repressor MDM2. Here, we observed S5A and the ubiquitin receptors ADRM1/PSMD16/hRpn13 and RAD23A and B functionally overlap in MDM2 degradation. We provide further evidence that degradation of only a subset of ubiquitinated proteins is sensitive to S5A knockdown because ubiquitin receptor redundancy is commonplace. p53 can be upregulated by S5A modulation while degradation of substrates with redundant receptors is maintained. Our observations and analysis of Cancer Dependency Map (DepMap) screens show S5A depletion/loss substantially reduces cancer cell line viability. This and selective S5A dependency of proteasomal substrates make S5A a target of interest for cancer therapy.
引用
收藏
页码:2746 / 2767
页数:22
相关论文
共 50 条
  • [1] The degradation of p53 and its major E3 ligase Mdm2 is differentially dependent on the proteasomal ubiquitin receptor S5a
    Sparks, A.
    Dayal, S.
    Das, J.
    Robertson, P.
    Menendez, S.
    Saville, M. K.
    ONCOGENE, 2014, 33 (38) : 4685 - 4696
  • [2] Controlled Access of p53 to the Nucleus Regulates Its Proteasomal Degradation by MDM2
    Davis, James R.
    Mossalam, Mohanad
    Lim, Carol S.
    MOLECULAR PHARMACEUTICS, 2013, 10 (04) : 1340 - 1349
  • [3] Inhibition of p53 degradation by Mdm2 acetylation
    Wang, XJ
    Taplick, J
    Geva, N
    Oren, M
    FEBS LETTERS, 2004, 561 (1-3): : 195 - 201
  • [4] Cocompartmentalization of p53 and Mdm2 is a major determinant for Mdm2-mediated degradation of p53
    Xirodimas, DP
    Stephen, CW
    Lane, DP
    EXPERIMENTAL CELL RESEARCH, 2001, 270 (01) : 66 - 77
  • [5] Ubiquitin-independent p53 proteasomal degradation
    Tsvetkov, P.
    Reuven, N.
    Shaul, Y.
    CELL DEATH AND DIFFERENTIATION, 2010, 17 (01) : 103 - 108
  • [6] Ubiquitin-independent p53 proteasomal degradation
    P Tsvetkov
    N Reuven
    Y Shaul
    Cell Death & Differentiation, 2010, 17 : 103 - 108
  • [7] P53 Mdm2 Inhibitors
    Khoury, Kareem
    Doemling, Alex
    CURRENT PHARMACEUTICAL DESIGN, 2012, 18 (30) : 4668 - 4678
  • [8] The degradation of p53 and its major E3 ligase Mdm2 is differentially dependent on the proteasomal ubiquitin receptor S5a
    A Sparks
    S Dayal
    J Das
    P Robertson
    S Menendez
    M K Saville
    Oncogene, 2014, 33 : 4685 - 4696
  • [9] The roles and regulation of MDM2 and MDMX: it is not just about p53
    Klein, Alyssa M.
    de Queiroz, Rafaela Muniz
    Venkatesh, Divya
    Prives, Carol
    GENES & DEVELOPMENT, 2021, 35 (9-10) : 575 - 601
  • [10] Transcriptional repressor NIR interacts with the p53-inhibiting ubiquitin ligase MDM2
    Heyne, Kristina
    Foerster, Juliane
    Schuele, Roland
    Roemer, Klaus
    NUCLEIC ACIDS RESEARCH, 2014, 42 (06) : 3565 - 3579